Loxapine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Loxapine: From Schizophrenia to Manic Bipolar Affective Disorder
One-Sentence Summary
Loxapine is a first-generation (typical) antipsychotic originally used to treat schizophrenia, with an inhaled formulation (Adasuve®) already approved abroad for acute agitation. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, a prediction reinforced by 20 supporting publications, including pooled Phase III RCT data — though it is not currently marketed in Canada.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (oral loxapine, first-generation/typical antipsychotic); inhaled formulation already approved in the US/EU for acute agitation |
| Predicted New Indication | Manic Bipolar Affective Disorder (acute agitation associated with bipolar mania) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
The formal DrugBank mechanism-of-action record for loxapine is currently a data gap in this evidence pack (DG002). However, the literature captured here consistently describes loxapine as a dibenzoxazepine-class, first-generation antipsychotic that acts primarily as a D2 dopamine / 5-HT2A serotonin receptor antagonist — the same mechanism shared by other agents used to control acute psychiatric agitation and mania.
The proposed new indication is not a distant extrapolation: an inhaled formulation of loxapine (Adasuve®, using the Staccato® delivery system) has already been approved in the United States and European Union specifically for the acute treatment of agitation associated with schizophrenia or bipolar I disorder. This means the “predicted” indication substantially overlaps with an already-established, regulator-approved use elsewhere — the TxGNN signal here reflects a real, mechanistically coherent extension rather than a purely speculative association.
Two Phase III randomized, placebo-controlled trials (referenced across multiple publications, e.g. NCT00628589 and NCT00721955) enrolled patients with either schizophrenia or bipolar I disorder experiencing acute agitation, and a head-to-head PLACID trial compared inhaled loxapine against intramuscular aripiprazole in the same population. This gives the bipolar-mania prediction a materially stronger evidence base than the other candidates in this evidence pack.
For transparency, nine additional TxGNN-predicted candidates (ranks 2–10, all scoring >99.8%) were also reviewed — including retinal dystrophy, hydranencephaly, X-linked myopia variants, a congenital glycosylation disorder, Charcot-Marie-Tooth type 1G, polymicrogyria, and atypical glycine encephalopathy. None have clinical trial or literature support, and none share a plausible mechanistic link to D2/5-HT2A antagonism (they are predominantly monogenic structural/metabolic disorders). All nine were scored L5 / Hold and are excluded from further evaluation in this report.
Clinical Trial Evidence
Currently no related clinical trials registered in ClinicalTrials.gov or ICTRP for this specific drug–disease pair (structured trial records were not retrieved). Note: the Literature Evidence below discusses two pivotal Phase III RCTs (NCT00628589, NCT00721955) and the PLACID trial by publication, but these were not captured as discrete clinical-trial registry records in this evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22226343 | 2012 | RCT (pooled analysis, 2 Phase III trials) | Int J Clin Pract | Pooled effect-size analysis of two pivotal Phase III RCTs of inhaled loxapine for agitation in schizophrenia/bipolar disorder |
| 29724638 | 2018 | RCT | Eur Neuropsychopharmacol | PLACID trial: assessor-blind RCT comparing inhaled loxapine vs. IM aripiprazole in acutely agitated schizophrenia/bipolar I patients across 23 centres |
| 28376877 | 2017 | RCT (protocol/design) | BMC Psychiatry | Study design paper for the PLACID randomized trial |
| 29163985 | 2017 | RCT (responder analysis) | BJPsych Open | PANSS-EC responder analysis from two Phase III RCTs (344 schizophrenia, 314 bipolar I patients) |
| 27151529 | 2016 | Systematic Review & Meta-analysis | Hum Psychopharmacol | Systematic review of short-term pharmacological interventions for agitation in schizophrenia/bipolar disorder |
| 35913401 | 2022 | Review | Expert Rev Neurother | 50-year experience review of loxapine for rapid non-coercive tranquilization of acute behavioral disturbances |
| 33460070 | 2020 | Review | Acta Psychiatr Scand | Evidence-based review of treatment options and clinical suggestions for bipolar mania |
| 30721526 | 2019 | Expert Review/Commentary | Drugs in R&D | Expert commentary on inhaled loxapine for acute agitation in bipolar disorder and schizophrenia |
| 31496709 | 2019 | Review | Neuropsychiatr Dis Treat | Safety, efficacy, and patient acceptability review of inhaled loxapine for acute agitation in bipolar I/schizophrenia |
| 28208695 | 2017 | Clinical Review | Int J Mol Sci | Narrative/clinical mini-review of efficacy and tolerability of inhaled loxapine for acute agitation |
Canada Market Information
Loxapine is currently not marketed in Canada — no Drug Identification Numbers (DINs) are on file (0 licenses recorded). Any Canadian development pathway for this indication would require a new submission rather than a label-extension of an existing authorization.
Safety Considerations
- Key Warnings: Formal Health Canada/TFDA label warnings have not yet been extracted for this drug (data gap, see below). However, the evidence pack’s mechanistic rationale notes that the inhaled loxapine formulation (Adasuve®) carries a boxed warning for bronchospasm and is subject to a Risk Evaluation and Mitigation Strategy (REMS) in jurisdictions where it is approved — this should be treated as a material safety signal pending formal label confirmation.
- Drug Interactions: No interaction data currently on file (query returned no results).
Please refer to the official package insert for complete safety information once available — formal contraindication and warning data for this drug have not yet been retrieved (see Conclusion below).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The bipolar-mania prediction is supported by a coherent mechanistic story (D2/5-HT2A antagonism), an existing approved use for the same drug in the same patient population abroad (inhaled loxapine for agitation in bipolar I disorder/schizophrenia in the US/EU), and 10+ relevant publications including pooled and head-to-head Phase III RCT data (L1 evidence). This is one of the stronger repurposing signals in this evidence pack — the other nine TxGNN candidates (ranks 2–10) lack any clinical, literature, or mechanistic support and were held.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain and parse the official Health Canada/TFDA-equivalent product label (warnings, contraindications) — this is currently blocking formal S1 safety screening.
- Resolve DG002: confirm loxapine’s formal DrugBank-sourced mechanism-of-action record to replace the rationale-derived MOA used in this report.
- Since loxapine is not currently marketed in Canada, determine the regulatory pathway (new submission vs. leveraging existing US/EU Adasuve approval data) before advancing further.
- Formal drug-interaction (DDI) profile, as the current query returned no results.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.